Agilent Technologies (NYSE:A) Given New $135.00 Price Target at Barclays

Agilent Technologies (NYSE:A) had its price target lowered by Barclays from $145.00 to $135.00 in a research note published on Wednesday morning, MarketBeat reports. The brokerage currently has an underweight rating on the medical research company’s stock.

A has been the subject of a number of other reports. TD Cowen lifted their price target on shares of Agilent Technologies from $153.00 to $160.00 and gave the company a “buy” rating in a research report on Thursday, August 22nd. Wells Fargo & Company began coverage on Agilent Technologies in a report on Tuesday, August 27th. They issued an “overweight” rating and a $157.00 price objective for the company. Sanford C. Bernstein reduced their target price on Agilent Technologies from $140.00 to $135.00 and set a “market perform” rating on the stock in a report on Tuesday. JPMorgan Chase & Co. dropped their price target on Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating for the company in a research note on Tuesday. Finally, StockNews.com downgraded shares of Agilent Technologies from a “buy” rating to a “hold” rating in a research note on Tuesday. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $143.40.

Agilent Technologies Trading Down 0.1 %

Shares of NYSE:A opened at $137.98 on Wednesday. The stock has a market cap of $39.65 billion, a PE ratio of 31.22, a P/E/G ratio of 4.38 and a beta of 1.07. The company has a quick ratio of 1.37, a current ratio of 2.09 and a debt-to-equity ratio of 0.57. Agilent Technologies has a 12-month low of $124.16 and a 12-month high of $155.35. The business has a 50 day moving average of $137.60 and a 200-day moving average of $137.37.

Agilent Technologies Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, January 22nd. Stockholders of record on Tuesday, December 31st will be issued a dividend of $0.248 per share. The ex-dividend date is Tuesday, December 31st. This is an increase from Agilent Technologies’s previous quarterly dividend of $0.24. This represents a $0.99 annualized dividend and a dividend yield of 0.72%. Agilent Technologies’s dividend payout ratio is 21.27%.

Insider Activity at Agilent Technologies

In other Agilent Technologies news, SVP Dominique Grau sold 9,990 shares of the business’s stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $145.00, for a total transaction of $1,448,550.00. Following the sale, the senior vice president now directly owns 40,011 shares of the company’s stock, valued at $5,801,595. The trade was a 19.98 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Hedge Funds Weigh In On Agilent Technologies

Several large investors have recently modified their holdings of A. Menard Financial Group LLC increased its holdings in Agilent Technologies by 1.6% in the second quarter. Menard Financial Group LLC now owns 4,845 shares of the medical research company’s stock valued at $628,000 after purchasing an additional 77 shares during the period. McAdam LLC grew its position in shares of Agilent Technologies by 3.1% in the 3rd quarter. McAdam LLC now owns 2,531 shares of the medical research company’s stock valued at $376,000 after buying an additional 77 shares during the last quarter. Brown Brothers Harriman & Co. increased its stake in shares of Agilent Technologies by 13.5% in the third quarter. Brown Brothers Harriman & Co. now owns 646 shares of the medical research company’s stock valued at $96,000 after buying an additional 77 shares during the period. Global Retirement Partners LLC raised its position in shares of Agilent Technologies by 3.2% during the third quarter. Global Retirement Partners LLC now owns 2,570 shares of the medical research company’s stock worth $382,000 after acquiring an additional 79 shares during the last quarter. Finally, Rovin Capital UT ADV lifted its stake in shares of Agilent Technologies by 1.6% in the third quarter. Rovin Capital UT ADV now owns 5,049 shares of the medical research company’s stock worth $750,000 after acquiring an additional 81 shares during the period.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.